NCT06211036: An ongoing trial by Amgen
This trial is ongoing. It must report results 1 year, 7 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06211036 |
|---|---|
| Title | A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 5, 2024 |
| Completion date | July 5, 2027 |
| Required reporting date | July 4, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Nov. 3, 2026 |
| Days late | None |